Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Tumor Lysis Syndrome × Urate Oxidase × Clear all

Phase

Phase 4 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1

Conditions

Tumor Lysis Syndrome 1 Neoplasms 1 Myelodysplastic Syndromes 1 Lymphoma 1 Leukemia 1 Hyperuricemia 1

Interventions

Allopurinol 2 venetoclax 1 rasburicase 1 obinutuzumab 1 Urate Oxidase 1 Febuxostat 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed

280 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡